Advertisement

Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy

  • Julia Alvaeus
  • Robert Rosenblatt
  • Markus Johansson
  • Farhood Alamdari
  • Tomasz Jakubczyk
  • Benny Holmström
  • Tammer Hemdan
  • Ylva Huge
  • Firas Aljabery
  • Susanne Gabrielsson
  • Katrine Riklund
  • Ola Winqvist
  • Amir SherifEmail author
Open Access
Original Article
  • 264 Downloads

Abstract

Purpose

To examine the relationship between the number of tumour draining sentinel nodes (SNs) and pathoanatomical outcomes, in muscle-invasive bladder cancer (MIBC), in patients undergoing neoadjuvant chemotherapy (NAC) and radical cystectomy (RC).

Materials and Methods

In an ongoing prospective multicenter study, we included 230 patients with suspected urothelial MIBC from ten Swedish urological centers. All underwent TURb and clinical staging. From the cohort, 116 patients with urothelial MIBC; cT2-cT4aN0M0, underwent radical cystectomy (RC) and lymphadenectomy with SN-detection (SNd). 83 patients received cisplatin-based NAC and 33 were NAC-naïve. The number and locations of detected SNs and non-SNs were recorded for each patient. The NAC treated patients were categorized by pathoanatomical outcomes post-RC into three groups: complete responders (CR), stable disease (SD) and progressive disease (PD). Selected covariates with possible impact on SN-yield were tested in uni -and multivariate analyses for NAC-treated patients only.

Results

In NAC treated patients, the mean number of SNs was significantly higher in CR patients (3.3) and SD patients (3.6) compared with PD patients (1.4) (p = 0.034). In a linear multivariate regression model, the number of harvested nodes was the only independent variable that affected the number of SNs (p = 0.0004).

Conclusions

The number of tumor-draining SNs in NAC-treated patients was significantly lower in patients with progressive disease.

Keywords

Urinary bladder neoplasms Neoadjuvant therapy Cisplatin Sentinel lymph node biopsy Cystectomy 

Introduction

Urinary bladder cancer (UBC) is the fourth most common malignancy in men and the eighth most common in women, in the Western world [1]. Approximately 25–30% of bladder tumours are muscle-invasive (MIBC) [1, 2]. MIBC is associated with high risk of regional and distant metastatic spread, the latter with a median survival of 15 months albeit maximum oncological treatment [3]. Treatment of localized MIBC (T2a-T4aN0M0) is radical cystectomy (RC) with regional lymphadenectomy (LND). However, despite radical excision, local recurrence or distant metastases develop in around 50% of patients, probably due to early micrometastases [4]. In attempts to eliminate early dissemination, cisplatin-based combination neoadjuvant chemotherapy (NAC) is recommended to all medically fit patients with clinically localized MIBC [5, 6]. NAC is administered systemically in 3–4 cycles pre-RC. NAC is associated with significant overall survival (OS) benefits; a large meta-analysis assigned it to an 8% absolute increase in 5-year OS [7]. Especially good survival benefits have been seen in patients where NAC induces complete downstaging (CD) of the primary tumour, suggesting CD to be a surrogate marker for efficacy on dissemination [8].

A sentinel node (SN) is defined as the primary tumour-draining lymph node (LN) [9] and is considered being the primary site of metastasis. Yet, evidence from recent years of SN-research in MIBC shows that the number of detectable SNs often exceed one single node [10, 11, 12]. SN-detection (SNd) can be performed by peritumoral injection of radioactive tracer and intraoperative examination with handheld γ-probe [11, 12, 13, 14]. Recently, fluorescence-guided intraoperative imaging of lymphatics, using Indocyanine green (ICG) shows promising results [15].

The SN-concept in MIBC was originally introduced with aims of improving identification of LN-metastases or determining the extent of LN-dissection. However, several studies have shown SN-detection to be of limited or no use in nodal staging [12, 14]. Instead, focus on SNd in MIBC has shifted to its role in immunobiological research [16, 17, 18, 19, 20, 21]. Because a SN is the compartment where the host immune system first encounters tumour-derived antigens, it is also a good site for extracting tumour reactive lymphocytes for use in adoptive T-cell immunotherapy [22, 23]. Recent SN-research also shows that NAC promotes antitumor T-cell responses in MIBC, by activating T-effector cells (Teffs) and reducing the immunosuppressive activity of regulatory T-cells (Tregs) in SNs. Higher Teff to activated Treg ratio has been established in patients where NAC has induced CD [21].

What remains unanswered is the relationship between the number of tumour-draining SNs and pathoanatomical responses to NAC. Considering the SN-role in the immune defence against cancer, we speculate that the greater the number of SNs in a patient, the higher the chance of non-progression due to NAC. In 2016 Rosenblatt et al. [14] reported on the feasibility of SN-detection in NAC-patients, regardless of pT-stage. We now investigate the number of SNs and its association to pathoanatomical status after NAC, in an enlarged prospective cohort.

Materials/patients

230 patients with suspected urothelial MIBC from ten Swedish urological centers were included in a non-randomized prospective trial. Enrolment started in May 2013 and closed in December 2018. Main inclusion criterion was suspected urothelial MIBC. Reasons for exclusion included; previous BCG-therapy, non-muscle invasive UBC following TURb and robot-assisted laparoscopic radical cystectomy (RARC). For all exclusion criteria, see flow chart (Fig. 1).
Fig. 1

Flow chart of patient inclusions and subgroups. In total, 230 patients were enrolled to undergo TURb for suspected urothelial MIBC. 56 patients were histopathologically diagnosed as non-muscle invasive bladder cancer (NMIBC) and subsequently excluded. 58 patients were excluded due to other reasons, listed in the figure. The remaining patients underwent cystectomy and sentinel node detection (n = 116) and was subgrouped according to NAC treatment status. The NAC-patients (n = 83) were further stratified into; complete response, CR, (pT0N0M0), stable disease (SD) (pTis-pT4aN0M0), and progressive disease (PD), (pTanyN+ and/or M+)

Methods

SNd by radioactive technetium was performed in a standardized fashion across all RC-centers as previously described [14]. A handheld intraoperative Geiger counter registered radioactivity in suspected lymph nodes, by counts per minute of ionization events (CPM). Lymph node detection was performed according to the intended same template: Bilateral Obturator fossae, External Iliac artery bilaterally, Common Iliac artery up to mid-level. Any in situ detected sentinel nodes at any other locations were also included apart from the intended template. Nodal specimens were defined by histopathology as true LNs or not. A true LN, w/wo metastasis, with detected CPM ≥ 10 was defined as a SN. If a nodal SN-specimen was found containing > 1 LN in the pathology evaluation, the detected CPM-value was divided by the number of contained nodes. Specimens with CPM > 10 not containing any lymphatic tissue, were false positive (FP)-detections. If an undetected specimen showed LN-metastasis, it was named a false negative (FN)-detection.

Statistics

Differences in numerical and ordinal variables were tested using one-way ANOVA. For categorical data, the Chi-squared test was used. Furthermore, selected covariates were analyzed in a multivariate linear model for possible confounders impacting SN-yield. Statistical analyses were performed in IBM SPSS 25 and 26.

Results

116 patients underwent RC and SNd (fig) and of these, 83 patients received 1–4 cycles of NAC and were stratified by pathoanatomical outcomes, into complete response (CR), (pT0N0M0), stable disease (SD) (pTis-pT4aN0M0) and progressive disease (PD) pTanyN+ and/or pM+ (Table 1).
Table 1

Patient characteristics

 

NAC

No NAC

All

All NAC

CR—complete response

SD—stable disease

PD—progressive disease

p value

Designation of outome

pT0N0M0

pTis-T4aN0M0

pTanyN+

 

All pT-stages

No. of patients

83

36

35

12

 

33

116

Age (mean)

 

67

66.8

69.3

0.61

75.8

69.7

Age (range)

39–80

39–79

39–79

58–80

 

57–87

39–87

Gender

    

0.91

  

 Male

66 (79.5)

28 (77.8)

28 (80)

10 (83.3)

 

19 (57.6)

85 (73.3)

 Female

17 (20.5)

8 (22.2)

7 (20)

2 (16.7)

 

14 (42.4)

31 (26.7)

Clinical stage

    

0.04

  

 cT2

63 (75.9)

32 (88.9)

24 (68.6)

7 (58.3)

 

23 (69.7)

86 (74.1)

 cT3

17 (20.5)

4 (11.1)

8 (22.9)

5 (41.7)

 

10 (30.3)

27 (23.3)

 cT4a

3 (3.6)

0

3 (8.6)

0

 

0

3 (2.6)

No. of NAC-cycles

    

0.86

  

 1

6 (7.2)

3 (8.3)

2 (5.7)

1 (8.3)

   

 2

9 (10.8)

1 (2.8)

6 (17.1)

2 (16.7)

   

 3

62 (74.7)

30 (83.3)

24 (68.6)

8 (66.7)

   

 4

6 (7.2)

2 (5.6)

3 (8.6)

1 (8.3)

   

NAC-type

    

0.89

  

 MVAC

25 (30.1)

11 (30.5)

11 (31.4)

3 (25)

   

 HD-MVAC

53 (63.9)

24 (66.7)

21 (60)

8 (66.7)

   

 Cisplatin-gemzar

4 (4.8)

1 (2.8)

2 (5.7)

1 (8.3)

   

 Carboplatin-gemzar

1 (1.2)

0

1 (2.9)

0

   

Baseline characteristics for all 116 cystectomized patients distributed over subgroups. Statistical analysis was applied on NAC-patients only. There were no statistical differences between NAC-subgroups in age, gender, number of NAC-cycles or NAC-type. NAC-subgroups differed significantly in clinical tumour stage pre-RC (p = 0.04)

NAC neoadjuvant chemotherapy, RC radical cystectomy, HD-MVAC high dose Methorexate, Vinblastine, Adriamycin, Cisplatin

In the NAC-treated cohort, clinicopathological factors were compared between the subgroups. There were no statistical differences in age, gender or number of NAC cycles (Table 1). The pathoanatomical outcomes in the NAC-treated cohort (n = 83), were CR in 43.4% (36/83), SD in 42.2% (35/83) and PD in 14.4% (12/83) (Table 2). NAC-subgroups differed significantly in clinical tumour stage pre-RC, with a higher number of cT3 and cT4 tumours in SD and PD-patients (p = 0.04). Interestingly, there were significant differences in mean and median number of SNs per patient in CR and SD compared to PD (p = 0.034). The SN-detection rate was 91.7% in CR-patients and 58.3% in PD-patients (Table 3). There were higher FP-detection rates in CR-patients (36.1%), compared to the overall FP-detection rate of 29.3% (p = 0.36) (Table 3). However, in a multivariate linear regression model, the only significant predictor for SNs was the number of harvested nodes (Table 4).
Table 2

Pathoanatomical outcomes

Final pTNM

NAC

No NAC

All

CR—complete response

SD—stable disease

PD—progressive disease

pT0N0M0

36

0

0

6

42

pTisN0M0

0

5

0

0

5

pTaN0M0

0

2

0

0

2

pT1N0M0

0

5

0

1

6

pT2N0M0

0

11

0

4

15

pT3N0M0

0

10

0

10

20

pT4aN0M0

0

2

0

1

3

pT0N+

0

0

1

0

1

pTisN+

0

0

1

0

1

pT2N+

0

0

4

0

4

pT3N+

0

0

5

7

12

pT4aN+

0

0

1

2

3

pT4bN+

0

0

0

1

1

Any M+

0

0

0

1

1

Final pTNM-stages post-cystectomy for all included patients, stratified by subgroups. In the NAC-treated cohort; Complete Response (CR) was found in 43.4% (36/83), Stable Disease in 42.2% (35/83) and Progressive Disease in 14.4% (12/83) of the patients

Table 3

True positive and false positive sentinel node detections

 

NAC

No NAC

All

All NAC

CR—complete response

SD—stable disease

PD—progressive disease

p value

Total no of harvested lymph nodes

1350

616

572

162

 

508

1858

Mean no of harvested lymph nodes

16.3

17.1

16.3

13.5

0.5

15.4

16

Sentinel nodes

 Total

262

120

125

17

 

102

364

 Mean

3.2

3.3

3.6

1.4

0.034

3.1

3.1

 Median

2

2.4

3

1

0.049

3

2.5

 Rate of detection %

85.5

91.7

88.6

58.3

 

75.8

82.8

False positive nodes

 Total

42

25

13

4

 

18

60

 Mean

0.51

0.69

0.37

0.33

0.36

0.55

0.52

 Rate of detection %

30.1

36.1

22.9

33.3

 

27.3

29.3

Total and mean number of harvested lymph nodes, true sentinel nodes and false positive detections, for all cystectomized patients and by subgroups. A true positive detection was defined as a radioactive specimen with > 10 CPM confirmed as a lymph node by histopathology. Detections with CPM > 10 which did not contain any lymphatic tissue, were labelled as false positive (FP). There was a significant difference in both mean and median number of SNs between the NAC-subgroups (p = 0.034 and p = 0.049)

CPM counts per minute (measured by Geiger probe intraoperatively), CR complete response, SD stable disease, PD progressive disease, NAC neoadjuvant chemotherapy

Table 4

Factors impacting SN-yield

Predictors

True SNs

Multivariate p value

Age

0.18

Gender

0.67

Total no harvested nodes

0.0004

No. of NAC-cycles

0.47

The total number of harvested lymph nodes was the only statistically significant predictor of SN yield

RC radical cystectomy, NAC neoadjuvant chemotherapy

Discussion

In the present study, we saw that the mean and median number of sentinel nodes (SN) were significantly lower in patients with progressive disease. This is, to our knowledge, the first time an association between SN yield and pathological outcome in NAC-treated MIBC, is recorded.

The finding could be explained by previous observations, namely that metastatic deposits appear to block lymph vessels or redirect the lymphatic flow resulting in a lowered rate of SN detection in patients with more advanced disease [11]. In addition, the biological role of the lymphatic system could be considered. These vessels are not passive venues for mechanical spread of cancer cells, but rather they play a major role in tumor immune responses [24, 25]. A recent experimental study showed that mice with ablated lymphatics exhibited reduced intra-tumoral accumulation of cytotoxic T cells and increased tumor PD-L1 expression, causing rapid tumor growth. Additionally, impaired function of the peritumoral lymphatic vessels resulted in decreased migration of dendritic cells to draining SNs compared with normal flank skin-draining lymph nodes [26].

Therefore, we hypothesize that the condition of the lymphatics might be reflected in the SN status. Conversely, a deficient lymphatic system could imply a state of immunodeficiency, which can result in reduced responsiveness to chemotherapy [21]. Thus, the number of SNs could hypothetically be a surrogate marker for antitumoral immunological activity, and perhaps, responsiveness to NAC.

Nevertheless, the association between the number of SNs and pathoanatomic outcomes must be interpreted with caution. For instance, the only factor that impacted the yield of SNs in our multivariate analysis was the total number of harvested lymph nodes. Several limitations of the study must be taken into consideration: First, the study is a retrospective analysis of a prospective cohort, meaning that the material was stratified and analyzed according to post-hoc constructed groups. Second, there were many centers with relatively few patients per center. This runs the risk of introducing bias due to heterogeneity in terms of individual urologic surgeons and pathologists. For example, individual lymph node dissection practices could theoretically cause variations in the LND template, since the template was predefined but not explicitly controlled for. Third, the time between injection of radioactive tracer and performed SNd may have varied by hours between patients, this due to intraoperative difficulties or different surgical techniques. A prolonged operation, allows the tracer to increasingly disperse throughout the entire lymphatic drainage line, leading to a suboptimal SNd. Fourth, peritumoral injections of technetium comes with technical challenges, especially in cases of large localized tumours or tumours located in diverticulae. For the fifth, the CPM-registration can be difficult to interpret. In some cases, there would be one reading in the surgical field but another on the dissection table.

With the approval of check-point inhibitors in late-stage urinary bladder cancer, there is a need to find good predictive markers for successful immunotherapy. In the future, patients with less advanced and non-disseminated tumours will probably undergo check-point inhibition. The main precondition for successful check-point inhibition is the very presence of active anti-tumourally directed T effector cells. A significantly reduced amount of T effector cells might indicate less efficacy of that kind of immunotherapy. Hence, a high number of sentinel nodes may be a candidate marker of mounted and functional immune responses valuable for adjuvant immunological therapy.

Conclusions and future perspectives

There was a significant difference in mean and median numbers of SNs after NAC, between patients with CR and SD compared to PD-patients, with a significantly lower number of SNs in patients with progressive disease. However, many factors impact the SN-yield. We hypothesize that the number of SNs might reflect the function of the regional lymphatic system, thus making SN-number a plausible surrogate marker for antitumoral immunological activity.

Notes

Acknowledgements

Open access funding provided by Umea University. This work was supported by the Swedish Cancer Society, the Wallenberg Foundation, the Swedish Medical Research Council, Regionala forskningsrådet i Uppsala-Örebroregionen (RFR in Uppsala-Örebro), the Swedish Research Council funding for clinical research in medicine (ALF) in Västerbotten, VLL, Sweden, The Cancer Research Foundations of Radiumhemmet, and the Cancer Research Foundation in Norrland, Umeå, Sweden. Research nurses Britt-Inger Dahlin and Kerstin Almroth (department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University) were of great assistance in the work. We also thank Marcus Thuresson at Statisticon AB, Uppsala, Sweden, for valuable support in the analysis of the statistics.

Author contributions

Protocol/project development: JA, RR, AS, OW, KR; Data collection or management: JA, MJ, FA, TJ, BH, TH, YH, FA, AS; Data analysis: JA, RR, AS; Manuscript writing/editing: JA, RR, AS, MJ, FA, TJ, BH, TH, YH, FA, SG; Funding: AS, OW, KR; Supervision: AS, RR.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and informed consent

This research involved human participants and all included patients have given their written and oral informed consent to participate. Inclusion was performed in two steps, for the first step—prior to TURb, all patients gave their informed consent as above stated. For the second step, patients proceeding to radical cystectomy, informed consent as above, was repeated.

References

  1. 1.
    Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L et al (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66(6 Suppl 1):4–34CrossRefGoogle Scholar
  2. 2.
    Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234–241CrossRefGoogle Scholar
  3. 3.
    von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068–3077CrossRefGoogle Scholar
  4. 4.
    Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long term results in 1054 patients. J Clin Oncol 19:666–675CrossRefGoogle Scholar
  5. 5.
    Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, De Santis M, Bruins HM et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71(3):462–475CrossRefGoogle Scholar
  6. 6.
    Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK et al (2011) A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 12(3):211–214CrossRefGoogle Scholar
  7. 7.
    Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA et al (2016) Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist 21(6):708–715CrossRefGoogle Scholar
  8. 8.
    Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullen A, Nilsson S et al (2012) Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 61(6):1229–1238CrossRefGoogle Scholar
  9. 9.
    Nieweg OE, Tanis PJ, Kroon BB (2001) The definition of a sentinel node. Ann Surg Oncol 8(6):538–541CrossRefGoogle Scholar
  10. 10.
    Sherif A, Garske U, Torre M, Thörn M (2006) Hybrid SPECT-CT: an additional technique for sentinel node detection of patients with invasive bladder cancer. Eur Urol 50(1):83–91CrossRefGoogle Scholar
  11. 11.
    Liedberg F, Chebil G, Davidsson T, Gudjonsson S, Mansson W (2006) Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer. J Urol 175(1):84–88 discussion 8–9 CrossRefGoogle Scholar
  12. 12.
    Aljabery F, Shabo I, Olsson H, Gimm O, Jahnson S (2017) Radio-guided sentinel lymph node detection and lymph node mapping in invasive urinary bladder cancer: a prospective clinical study. BJU Int 120(3):329–336CrossRefGoogle Scholar
  13. 13.
    Sherif A, De La Torre M, Malmstrom PU, Thorn M (2001) Lymphatic mapping and detection of sentinel nodes in patients with bladder cancer. J Urol 166(3):812–815CrossRefGoogle Scholar
  14. 14.
    Rosenblatt R, Johansson M, Alamdari F, Sidiki A, Holmstrom B, Hansson J et al (2017) Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report. World J Urol 35(6):921–927CrossRefGoogle Scholar
  15. 15.
    Patel MN, Hemal AK (2016) Molecular targeted fluorescence-guided intraoperative imaging of bladder cancer nodal drainage using indocyanine green during radical and partial cystectomy. Curr Urol Rep 17(10):74CrossRefGoogle Scholar
  16. 16.
    Malmstrom PU, Ren ZP, Sherif A, de la Torre M, Wester K, Thorn M (2002) Early metastatic progression of bladder carcinoma: molecular profile of primary tumor and sentinel lymph node. J Urol 168(5):2240–2244CrossRefGoogle Scholar
  17. 17.
    Marits P, Karlsson M, Sherif A, Garske U, Thorn M, Winqvist O (2006) Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. Eur Urol 49(1):59–70CrossRefGoogle Scholar
  18. 18.
    Hartana CA, Ahlén Bergman E, Zirakzadeh AA, Krantz D, Winerdal ME, Winerdal M et al (2018) Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFβ2 mediated pathway. PLoS ONE 13(7):e0200079CrossRefGoogle Scholar
  19. 19.
    Ahlén Bergman E, Hartana CA, Johansson M, Linton LB, Berglund S, Hyllienmark M et al (2018) Increased CD4+ T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients. Clin Epigenetics 10(1):102CrossRefGoogle Scholar
  20. 20.
    Hartana CA, Ahlén Bergman E, Broomé A, Berglund S, Johansson M, Alamdari F et al (2018) Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer. Clin Exp Immunol 194(1):39–53CrossRefGoogle Scholar
  21. 21.
    Krantz D, Hartana CA, Winerdal ME, Johansson M, Alamdari F, Jakubczyk T et al (2018) Neoadjuvant chemotherapy reinforces antitumour T cell response in urothelial urinary bladder cancer. Eur Urol 74(6):688–692CrossRefGoogle Scholar
  22. 22.
    Sherif A, Hasan MN, Marits P, Karlsson M, Winqvist O, Thörn M (2010) Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept. Eur Urol 58(1):105–111CrossRefGoogle Scholar
  23. 23.
    Sherif A, Hasan MN, Radecka E, Rodriguez AL, Shabo S, Karlsson M et al (2015) Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer. Scand J Urol 49(6):453–462CrossRefGoogle Scholar
  24. 24.
    Lund AW, Wagner M, Fankhauser M, Steinskog ES, Broggi MA, Spranger S et al (2016) Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Investig 126(9):3389–3402CrossRefGoogle Scholar
  25. 25.
    Swartz MA (2014) Immunomodulatory roles of lymphatic vessels in cancer progression. Cancer Immunol Res 2(8):701–707CrossRefGoogle Scholar
  26. 26.
    Kataru RP, Ly CL, Shin J, Park HJ, Baik JE, Rehal S, Ortega S, Lyden D, Mehrara BJ (2019) Tumor lymphatic function regulates tumor inflammatory and immunosuppressive microenvironments. Cancer Immunol Res.  https://doi.org/10.1158/2326-6066.CIR-18-0337 CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Julia Alvaeus
    • 1
  • Robert Rosenblatt
    • 1
    • 2
  • Markus Johansson
    • 1
    • 3
  • Farhood Alamdari
    • 4
  • Tomasz Jakubczyk
    • 5
  • Benny Holmström
    • 6
  • Tammer Hemdan
    • 6
  • Ylva Huge
    • 7
  • Firas Aljabery
    • 7
  • Susanne Gabrielsson
    • 8
  • Katrine Riklund
    • 9
  • Ola Winqvist
    • 10
  • Amir Sherif
    • 1
    Email author
  1. 1.Department of Surgical and Perioperative Sciences, Urology and AndrologyUmeå UniversityUmeåSweden
  2. 2.Department of UrologyKarolinska InstitutetStockholm South General HospitalStockholmSweden
  3. 3.Department of UrologySundsvall HospitalSundsvallSweden
  4. 4.Department of UrologyVästmanland HospitalVästeråsSweden
  5. 5.Department of UrologyLänssjukhuset RyhovJönköpingSweden
  6. 6.Department of Surgical SciencesUppsala UniversityUppsalaSweden
  7. 7.Division of Urology, Department of Clinical and Experimental MedicineLinköping UniversityLinköpingSweden
  8. 8.Division of Immunology and Allergy, Department of Medicine SolnaKarolinska InstitutetStockholmSweden
  9. 9.Department of Radiation SciencesUmeå UniversityUmeåSweden
  10. 10.Department of Clinical ImmunologyKarolinska University HospitalStockholmSweden

Personalised recommendations